choppi lsag hit roadblock small
molecul spend grind halt
core growth miss mark margin stabl
sale yoy fx vs est
core growth vs estimate guid despit
top-lin miss margin solid gm ahead est adj
opm in-lin mix benefit cost-cut non-gaap ep
lsag headwind concentr food small mol
lsag saw organ sale declin vs estimate weak demand china
grew qtr food sale declin government lab yet
resum purchas addit china initi lower gener drug price
pressur demand liquid chromatographi lc product use drug mfg
qualiti control demand small molecul lc product also declin develop
pharma puzzl albeit call similar small molecul headwind link
contrast demand product use larg biomolecul biolog remain
robust like explain differenti result
pharma sale tie small molecul vs much heavili
weight toward larg molecul slow china demand seen
link link elsewher portfolio saw core growth dgg line core
acg ahead thu dont think print death knell tool sector
trim est po see offset buyback
expect share trade miss encourag margin
resili abil deploy capit share buyback off-set ep hit
lower estim po reiter buy rate share new
organ growth estim vs
prior believ lsag weak may take time revers remain
posit rest underli market given posit commentari peer
sustain perform dgg acg ep estim lower
due buyback po move base
ebitda estim in-lin peer vs prior ebitda
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart santa clara california agil
technolog lead supplier analyt
instrument consum product
use mainli research qualiti assur
applic custom life scienc
chemic analysi industri compani
known leader life scienc
industri long histori innov
well posit benefit
secular posit growth trend life
scienc chemic analysi food
environment test acquisit also
provid new opportun growth
under-penetrated market agil reduc
cyclic exposur restructur
spin electron test measur
busi keysight help unlock sharehold
valu increas strateg flexibl
po base ev/ebitda multipl in-lin agil life
scienc peer group believ justifi given agil margin expans
potenti upsid new gc product cycl macro improv solid organ
revenu growth outlook strateg option opportun capit deploy
risk po econom risk fx risk slower expect uptak new
product expans new market competit risk reduct spend
integr risk takeout specul overhang
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
